In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Boston Scientific to acquire the rest of Veniti for $108mm plus earn-outs

Executive Summary

Boston Scientific Corp. agreed to paid $108mm in cash up front to acquire the remaining 75% of cardiovascular stent developer Veniti Inc. that it does not already own. The deal also includes up to $52mm in in earn-outs tied to FDA approval of Veniti’s flagship product.
Deal Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Includes Earnout
    • Partial Acquisition

Related Companies